Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.

Aleksandra Bogucka-FedorczukAnna CzyzElżbieta KalicińskaMateusz SawickiMagdalena Laszkowska-LewkoKatarzyna Wicherska-PawłowskaJustyna RybkaAgnieszka SzeremetIwona PrajsDonata SzymczakTomasz Wróbel

Published in: Journal of clinical apheresis (2020)

Our findings confirm higher HSC mobilization efficacy of Ara-C compared to Cy in MM patients. However, lower transfusions rate and better disease control of Cy may justify its use in some cases.

Keyphrases

hematopoietic stem cell
multiple myeloma
end stage renal disease
high dose
acute myeloid leukemia
low dose
prognostic factors
peritoneal dialysis